search
Back to results

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Primary Purpose

Advanced Malignant Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Sponsored by
Molecular Partners AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Malignant Solid Tumor focused on measuring Designed ankyrin repeat protein, DARPin®, fibroblast activation protein, CD40 antigen, advanced malignant solid neoplasm, relapsed malignant solid neoplasm, refractory malignant solid neoplasm

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Has an advanced, histologically-proven solid tumor of one of the following types, and for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or unable to tolerate other treatments:

    1. Colorectal cancer
    2. Ovarian cancer
    3. Endometrial cancer
    4. Gastric cancer
    5. Pancreatic cancer
    6. Anal cancer
    7. Cervical cancer
    8. Head and neck squamous cell carcinoma (HNSCC)
    9. Mesothelioma
    10. Prostate cancer
    11. Non-small cell lung cancer (NSCLC)
    12. Melanoma
    13. Urothelial/bladder cancer
    14. Microsatellite instability high cancer of any type
    15. Cutaneous squamous cell cancer
    16. Breast cancer
  2. Has signed and dated written informed consent before performing any study procedure, including screening
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1
  4. Anticipated life expectancy ≥ 12 weeks by Investigator judgement
  5. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  6. Should agree to undergo mandatory paired (pre and on-treatment) tumor biopsies and be considered to have biopsiable disease. The biopsies should be performed as follows:

    1. At least 1 tumor lesion ≥ 20 mm amenable to percutaneous biopsy other than the target lesion(s) used to follow response as defined by RECIST v1.1.
    2. For cutaneous or subcutaneous lesions, tumors should be ≥ 5 mm in diameter amenable to biopsy by excisional or punch biopsies without unacceptable risk of a major procedural complication.
    3. For core needle biopsy specimens, at least 3 to 6 cores with an 18-gauge needle should be collected.
    4. The on-treatment tumor biopsy should be taken from the same lesion as the pre-treatment biopsy. The biopsied lesion should be large enough to take both biopsies ≥ 1 cm apart.
  7. Should agree to undergo mandatory paired (pre and on-treatment) skin biopsies
  8. At least 28 days must have elapsed between any prior major surgery and screening. The following procedures are not considered major:

    1. Obtaining the pre-treatment tumor and skin biopsies as per protocol requirements
    2. Placement of a port for central venous access
    3. Needle, punch or excisional biopsy of a clinically or radiographically detected lesion
  9. Laboratory parameters at screening:

    a. Hematology: i. Platelet count ≥ 100,000 cells/mm3 ii. Absolute neutrophil count ≥ 1,000 cells/mm3 iii. Hemoglobin ≥ 9 g/dL b. Serum creatinine < 1.5 x upper limit of normal (ULN) or creatinine clearance > 50 mL/min on the basis of Cockcroft-Gault glomerular filtration rate estimation c. Coagulation: i. International normalized ratio (INR) < 1.5 ii. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless therapeutically warranted d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN e. Bilirubin normal, except for patients with known familial hyperbilirubinemia (such as Gilbert syndrome); for patients with documented Gilbert's syndrome (Gilbert-Meulengracht syndrome) total bilirubin ≤ 3 x ULN is acceptable f. Albumin > 2.8 g/dL or > 28 g/L, and without albumin transfusion for ≥ 7 days before screening

  10. Is using highly effective contraception, for females of childbearing potential (FCBP) and for men, as follows:

    1. Female: Is not pregnant, is not breastfeeding, and one of the following applies:

      • Not a FCBP
      • A FCBP who agrees and/or whose male partner agrees to follow the contraceptive guidance from screening, during the treatment period, and for at least 3 months after the last study drug administration. A FCBP must have a negative serum pregnancy test result at screening.

Male: Agreement to use a highly effective contraception method from screening, during the treatment period, and for at least 3 months after the last study drug administration and to refrain from donating sperm during this period.

Exclusion criteria:

  1. Known hypersensitivity to excipients used in the MP0317 formulation
  2. Autoimmune diseases, except autoimmune endocrinopathies that are stable with hormone replacement therapy
  3. Inflammatory diseases such as arthritis, colitis, liver fibrosis, cirrhosis, interstitial fibrosis or chronic obstructive pulmonary disease (COPD) that may have elevated tissue fibroblast activation protein (FAP) expression unless approved after consultation with the Sponsor
  4. Serious illness or concomitant non-oncological disease considered by the Investigator to be incompatible with participating in the protocol
  5. Left ventricular ejection fraction of < 50% on echocardiographic exam or multi-gated acquisition (MUGA) scan at screening
  6. History or evidence of clinically significant cardiovascular disease defined as at least one of the following criteria:

    1. Evidence of poorly controlled arterial hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg)
    2. Myocardial infarction or instable angina pectoris within 6 months before screening
    3. Heart failure (New York Heart Association Class III or IV)
    4. Any cardiac arrhythmia that is not well controlled
    5. QT corrected (QTc) prolongation ≥ Grade 2 (> 480 ms) at screening measured on 2 separate electrocardiograms (ECG) at least 10 minutes apart
    6. Clinically significant valvular heart disease
  7. Severe dyspnea, pulmonary dysfunction or need for continuous supportive oxygen inhalation
  8. Arterial thromboembolic event, stroke or transient ischemia attack within 12 months before screening
  9. Known central nervous system (CNS) metastases that are either untreated or are treated but are associated with clinical symptoms (e.g. headache, convulsions); patients with CNS metastases that have been treated with radiotherapy and/or surgery are eligible if they are clinically without symptoms for at least 6 weeks before screening; if under treatment with corticosteroids (not exceeding 10 mg/day prednisone or equivalent) and/or anticonvulsive agents, patients must be on a stable dose for at least 14 days before first study drug administration.
  10. Active uncontrolled bleeding or a bleeding diathesis
  11. Therapy for active infection needs to be completed at least 7 days before first study drug administration
  12. Known positivity for human immunodeficiency virus (HIV) or history of HIV (HIV testing is not mandatory)
  13. Active hepatitis B (chronic or acute; HBV) defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Patients with past or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antigen antibody test) are eligible.
  14. Active hepatitis C (HCV) infection defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test. Patients who are positive for HCV antibodies are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  15. Serious or non-healing wound, skin ulcer or non-healing bone fracture
  16. Abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months before screening
  17. Any vaccines within 28 days before first study drug administration
  18. An allogenic tissue/solid organ transplant
  19. History of another primary malignancy except for:

    1. Malignancy treated with curative intent and with no known active disease ≥ 2 years before screening and of relatively low potential risk for recurrence
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of residual disease
    3. Adequately treated carcinoma in situ without evidence of disease
    4. Cancer patients with incidental histologic findings of prostate cancer that, in the opinion of the Investigator, is not deemed to require active therapy (e.g. incidental prostate cancer identified following cystoprostatectomy that is tumor/node/metastasis Stage ≤ pT2N0) may be eligible, pending discussion and approval by the Sponsor
  20. Previous treatment with a DARPin® molecule
  21. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or it is the follow-up period of an interventional study
  22. Use of an investigational agent within 28 days before first study drug administration
  23. Any anticancer treatment, including chemotherapy, hormonal therapy or radiotherapy, within 21 days before first study drug administration; however, the following are allowed:

    1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists or antagonists
    2. Hormone-replacement therapy or oral contraceptives
    3. Palliative radiotherapy for bone metastases within 14 days before first study drug administration
  24. Continuous corticosteroid use exceeding 10 mg/day prednisone or equivalent
  25. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational medicinal product (IMP) or interpretation of the patient's data
  26. Unable or unwilling to comply with all study requirements for clinical visits, examinations, tests and procedures
  27. Patient deprived of liberty by a judicial or administrative decision, patient admitted to a social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation

Sites / Locations

  • Centre Léon BérardRecruiting
  • IUCT-O Institut Claudius RégaudRecruiting
  • NKI-AvLRecruiting
  • UMCURecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Dose-escalation Cohorts (q3w)

Dose-escalation Cohorts (q1w)

Arm Description

The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned. Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.

The starting dose is 0,5 mg/kg every week (q1w) and up to 3 dose levels are planned. Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.

Outcomes

Primary Outcome Measures

Type, incidence and severity of AEs and serious adverse events (SAEs)
According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Incidence of dose-limiting toxicities (DLTs)
DLTs will be reviewed as a subset of AEs that occur within 4 weeks after first study drug administration
Maximum tolerated dose (MTD)
Based on occurrence of DLTs within an adaptive study design following Bayesian Logistic Regression Model (BLRM)
Recommended dose for expansion (RDE)
Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and SAEs

Secondary Outcome Measures

Serum concentration-time profiles
Including parameters like maximum serum concentration (Cmax), time at Cmax (Tmax), minimal serum concentration (Cmin)
Area under the serum curve (AUC)
Pharmacokinetic (PK) analysis of MP0317
Total clearance (CL)
PK analysis of MP0317
Volume of distribution at steady state (Vss)
PK analysis of MP0317
Half-life (t1/2)
PK analysis of MP0317
Overall response rate (ORR)
Proportion of participants with complete response (CR) and partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)
Disease control rate (DCR)
Best overall response (BOR) of CR, PR or stable disease (SD) lasting 4 or more weeks following first study drug administration
Duration of response (DOR) of CR or PR
For participants with CR or PR, DOR will be calculated as the time from CR or PR to progressive disease (PD) or death.
Time to progression (TTP)
Time from first study drug administration to PD
Progression-free survival (PFS)
Time from first study drug administration to PD or death
Overall survival (OS)
Time from first study drug administration to death of any cause

Full Information

First Posted
September 30, 2021
Last Updated
May 25, 2023
Sponsor
Molecular Partners AG
search

1. Study Identification

Unique Protocol Identification Number
NCT05098405
Brief Title
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Official Title
A Phase 1, First-in-human, Multicenter, Open-label, Dose-escalation Study to Characterize the Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 11, 2021 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Molecular Partners AG

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40. Preclinical studies suggest that MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP and for which approved therapies have been exhausted. This is the first study of MP0317 in humans and its main purpose is to test its safety and tolerability in patients with advanced solid tumors. This study will also examine the blood levels of MP0317 at several increasing dose levels and a recommended dose for further development will be determined. The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Malignant Solid Tumor
Keywords
Designed ankyrin repeat protein, DARPin®, fibroblast activation protein, CD40 antigen, advanced malignant solid neoplasm, relapsed malignant solid neoplasm, refractory malignant solid neoplasm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose-escalation Cohorts (q3w)
Arm Type
Experimental
Arm Description
The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned. Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.
Arm Title
Dose-escalation Cohorts (q1w)
Arm Type
Experimental
Arm Description
The starting dose is 0,5 mg/kg every week (q1w) and up to 3 dose levels are planned. Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first.
Intervention Type
Drug
Intervention Name(s)
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)
Intervention Description
The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD). Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population. Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Intervention Type
Drug
Intervention Name(s)
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Intervention Description
The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD). Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population. Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Primary Outcome Measure Information:
Title
Type, incidence and severity of AEs and serious adverse events (SAEs)
Description
According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Time Frame
From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)
Title
Incidence of dose-limiting toxicities (DLTs)
Description
DLTs will be reviewed as a subset of AEs that occur within 4 weeks after first study drug administration
Time Frame
4 weeks after first study drug administration
Title
Maximum tolerated dose (MTD)
Description
Based on occurrence of DLTs within an adaptive study design following Bayesian Logistic Regression Model (BLRM)
Time Frame
From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)
Title
Recommended dose for expansion (RDE)
Description
Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and SAEs
Time Frame
From first study drug administration and until 28 days after the last study drug administration or end of study (EOS)
Secondary Outcome Measure Information:
Title
Serum concentration-time profiles
Description
Including parameters like maximum serum concentration (Cmax), time at Cmax (Tmax), minimal serum concentration (Cmin)
Time Frame
4.5 months
Title
Area under the serum curve (AUC)
Description
Pharmacokinetic (PK) analysis of MP0317
Time Frame
4.5 months
Title
Total clearance (CL)
Description
PK analysis of MP0317
Time Frame
4.5 months
Title
Volume of distribution at steady state (Vss)
Description
PK analysis of MP0317
Time Frame
4.5 months
Title
Half-life (t1/2)
Description
PK analysis of MP0317
Time Frame
4.5 months
Title
Overall response rate (ORR)
Description
Proportion of participants with complete response (CR) and partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)
Time Frame
4.5 months
Title
Disease control rate (DCR)
Description
Best overall response (BOR) of CR, PR or stable disease (SD) lasting 4 or more weeks following first study drug administration
Time Frame
4.5 months
Title
Duration of response (DOR) of CR or PR
Description
For participants with CR or PR, DOR will be calculated as the time from CR or PR to progressive disease (PD) or death.
Time Frame
4.5 months
Title
Time to progression (TTP)
Description
Time from first study drug administration to PD
Time Frame
4.5 months
Title
Progression-free survival (PFS)
Description
Time from first study drug administration to PD or death
Time Frame
4.5 months
Title
Overall survival (OS)
Description
Time from first study drug administration to death of any cause
Time Frame
12 months; including 4.5 months survival follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has an advanced, histologically-proven solid tumor of one of the following types, and for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or unable to tolerate other treatments: Colorectal cancer Ovarian cancer Endometrial cancer Gastric cancer Pancreatic cancer Anal cancer Cervical cancer Head and neck squamous cell carcinoma (HNSCC) Mesothelioma Prostate cancer Non-small cell lung cancer (NSCLC) Melanoma Urothelial/bladder cancer Microsatellite instability high cancer of any type Cutaneous squamous cell cancer Breast cancer Has signed and dated written informed consent before performing any study procedure, including screening Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 Anticipated life expectancy ≥ 12 weeks by Investigator judgement Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Should agree to undergo mandatory paired (pre and on-treatment) tumor biopsies and be considered to have biopsiable disease. The biopsies should be performed as follows: At least 1 tumor lesion ≥ 20 mm amenable to percutaneous biopsy other than the target lesion(s) used to follow response as defined by RECIST v1.1. For cutaneous or subcutaneous lesions, tumors should be ≥ 5 mm in diameter amenable to biopsy by excisional or punch biopsies without unacceptable risk of a major procedural complication. For core needle biopsy specimens, at least 3 to 6 cores with an 18-gauge needle should be collected. The on-treatment tumor biopsy should be taken from the same lesion as the pre-treatment biopsy. The biopsied lesion should be large enough to take both biopsies ≥ 1 cm apart. Should agree to undergo mandatory paired (pre and on-treatment) skin biopsies At least 28 days must have elapsed between any prior major surgery and screening. The following procedures are not considered major: Obtaining the pre-treatment tumor and skin biopsies as per protocol requirements Placement of a port for central venous access Needle, punch or excisional biopsy of a clinically or radiographically detected lesion Laboratory parameters at screening: a. Hematology: i. Platelet count ≥ 100,000 cells/mm3 ii. Absolute neutrophil count ≥ 1,000 cells/mm3 iii. Hemoglobin ≥ 9 g/dL b. Serum creatinine < 1.5 x upper limit of normal (ULN) or creatinine clearance > 50 mL/min on the basis of Cockcroft-Gault glomerular filtration rate estimation c. Coagulation: i. International normalized ratio (INR) < 1.5 ii. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless therapeutically warranted d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN e. Bilirubin normal, except for patients with known familial hyperbilirubinemia (such as Gilbert syndrome); for patients with documented Gilbert's syndrome (Gilbert-Meulengracht syndrome) total bilirubin ≤ 3 x ULN is acceptable f. Albumin > 2.8 g/dL or > 28 g/L, and without albumin transfusion for ≥ 7 days before screening Is using highly effective contraception, for females of childbearing potential (FCBP) and for men, as follows: Female: Is not pregnant, is not breastfeeding, and one of the following applies: Not a FCBP A FCBP who agrees and/or whose male partner agrees to follow the contraceptive guidance from screening, during the treatment period, and for at least 3 months after the last study drug administration. A FCBP must have a negative serum pregnancy test result at screening. Male: Agreement to use a highly effective contraception method from screening, during the treatment period, and for at least 3 months after the last study drug administration and to refrain from donating sperm during this period. Exclusion criteria: Known hypersensitivity to excipients used in the MP0317 formulation Autoimmune diseases, except autoimmune endocrinopathies that are stable with hormone replacement therapy Inflammatory diseases such as arthritis, colitis, liver fibrosis, cirrhosis, interstitial fibrosis or chronic obstructive pulmonary disease (COPD) that may have elevated tissue fibroblast activation protein (FAP) expression unless approved after consultation with the Sponsor Serious illness or concomitant non-oncological disease considered by the Investigator to be incompatible with participating in the protocol Left ventricular ejection fraction of < 50% on echocardiographic exam or multi-gated acquisition (MUGA) scan at screening History or evidence of clinically significant cardiovascular disease defined as at least one of the following criteria: Evidence of poorly controlled arterial hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) Myocardial infarction or instable angina pectoris within 6 months before screening Heart failure (New York Heart Association Class III or IV) Any cardiac arrhythmia that is not well controlled QT corrected (QTc) prolongation ≥ Grade 2 (> 480 ms) at screening measured on 2 separate electrocardiograms (ECG) at least 10 minutes apart Clinically significant valvular heart disease Severe dyspnea, pulmonary dysfunction or need for continuous supportive oxygen inhalation Arterial thromboembolic event, stroke or transient ischemia attack within 12 months before screening Known central nervous system (CNS) metastases that are either untreated or are treated but are associated with clinical symptoms (e.g. headache, convulsions); patients with CNS metastases that have been treated with radiotherapy and/or surgery are eligible if they are clinically without symptoms for at least 6 weeks before screening; if under treatment with corticosteroids (not exceeding 10 mg/day prednisone or equivalent) and/or anticonvulsive agents, patients must be on a stable dose for at least 14 days before first study drug administration. Active uncontrolled bleeding or a bleeding diathesis Therapy for active infection needs to be completed at least 7 days before first study drug administration Known positivity for human immunodeficiency virus (HIV) or history of HIV (HIV testing is not mandatory) Active hepatitis B (chronic or acute; HBV) defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Patients with past or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antigen antibody test) are eligible. Active hepatitis C (HCV) infection defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test. Patients who are positive for HCV antibodies are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. Serious or non-healing wound, skin ulcer or non-healing bone fracture Abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months before screening Any vaccines within 28 days before first study drug administration An allogenic tissue/solid organ transplant History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease ≥ 2 years before screening and of relatively low potential risk for recurrence Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of residual disease Adequately treated carcinoma in situ without evidence of disease Cancer patients with incidental histologic findings of prostate cancer that, in the opinion of the Investigator, is not deemed to require active therapy (e.g. incidental prostate cancer identified following cystoprostatectomy that is tumor/node/metastasis Stage ≤ pT2N0) may be eligible, pending discussion and approval by the Sponsor Previous treatment with a DARPin® molecule Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or it is the follow-up period of an interventional study Use of an investigational agent within 28 days before first study drug administration Any anticancer treatment, including chemotherapy, hormonal therapy or radiotherapy, within 21 days before first study drug administration; however, the following are allowed: Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists or antagonists Hormone-replacement therapy or oral contraceptives Palliative radiotherapy for bone metastases within 14 days before first study drug administration Continuous corticosteroid use exceeding 10 mg/day prednisone or equivalent Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational medicinal product (IMP) or interpretation of the patient's data Unable or unwilling to comply with all study requirements for clinical visits, examinations, tests and procedures Patient deprived of liberty by a judicial or administrative decision, patient admitted to a social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Medical Director MPAG
Phone
+41 44 755 77 00
Email
info@molecularpartners.com
Facility Information:
Facility Name
Centre Léon Bérard
City
Lyon
State/Province
Cedex 08
ZIP/Postal Code
69373
Country
France
Individual Site Status
Recruiting
Facility Name
IUCT-O Institut Claudius Régaud
City
Toulouse
State/Province
Cedex 09
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Name
NKI-AvL
City
Amsterdam
ZIP/Postal Code
1066 CX
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
UMCU
City
Utrecht
ZIP/Postal Code
3584 CW
Country
Netherlands
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
35319751
Citation
Rigamonti N, Veitonmaki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, Bessey R, Lekishvili T, Malvezzi F, Gachechiladze M, Behe M, Levitsky V, Trail PA. A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. Cancer Immunol Res. 2022 May 3;10(5):626-640. doi: 10.1158/2326-6066.CIR-21-0553.
Results Reference
derived

Learn more about this trial

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

We'll reach out to this number within 24 hrs